Measuring Outcomes to Improve Quality

Rheumatology Practice Management April 2016 Vol 4 No 2 - Reimbursement
Chase Doyle

Medicare is poised to incorporate new quality metrics as a guide for payments. At ASH 2015, Helen Burstin, MD, MPH, Chief Scientific Officer, National Quality Forum, Washington, DC, discussed the need for measures and reporting systems that reflect patient care and care coordination.

“The purpose of measurement is to improve healthcare quality,” said Dr Burstin.

To this end, Dr Burstin and colleagues considered the use of measurements based on episode of care rather than costs reflected in individual claims.

“How do you move from a population at risk all the way through the acute management of illness to postacute care and secondary prevention?” Dr Burstin asked. “What kind of outcome measures could be used to describe that space?”

Although measures such as functional status, quality of life, costs, and advance care planning are a component of that, a more comprehensive set of measures is needed, according to Dr Burstin. At the same time, as consumers and purchasers seek out better data, tensions between system-level measurement and individual assessment arise. Metrics are therefore needed for different specialists and settings.

Measuring Outcomes

“Outcomes are the reasons patients seek care, and why providers deliver care,” she said. “Outcomes are integrative, reflecting the result of all care provided over a particular time period. In addition, measuring performance on outcomes encourages a ‘systems approach’ to providing and improving care rather than narrow process measures.”

In addition, “measuring outcomes encourages innovation in identifying ways to improve outcomes that might not previously have been considered modifiable,” she added.

An underutilized example of this is patient-reported outcomes. “Researchers have developed an elegant set of tools for patients,” said Dr Burstin. “These are well-validated patient-level instruments.”

And yet, there are challenges to using patient-reported outcomes for accountability and performance improvement, she said, because little is known about how to aggregate this information.

Unintended Consequences

Despite the upside to measuring outcomes, persistent measurement gaps have been identified. “There is a real concern around potential for unintended consequences,” Dr Burstin cautioned. “We don’t want to be incentivizing bad medical decisions.”

There are also challenges with accountability, as patient selection can lead to significant differences across physicians or hospitals. Furthermore, outcomes reflect a variety of factors, not all related to the care provided. “Some of these factors are patient-related,” she said. “Some of which are modifiable, and some of which are not.”

These factors include genetics, demographic characteristics, clinical factors, psychosocial factors, and socioeconomic and environmental factors. There are also health-related behaviors and activities (eg, tobacco, diet) to consider. Finally, risk adjustments can be made for socioeconomic status, too, although this remains controversial.

Discussing her study, she said, “There was a huge dichotomy of opinion between those who thought adjustment for socioeconomic status was necessary for the sake of comparative performance, and those who thought it would mask disparities and not move us forward.”

While acknowledging that the move toward more episode-based, value-based purchasing is not going to be easy, Dr Burstin is encouraged by support from multiple stakeholders.

“We are hearing a great deal of interest, not just from the public side, but from the commercial side, and health clinic world, as well,” she concluded. “It’s a move that needs to be made,” Dr Burstin said.

Related Items
Understanding the Quality Payment Program
Andrea Zlatkus, CPM, CHRC
Rheumatology Practice Management February 2017 Vol 5 No 1 published on March 2, 2017 in Reimbursement
Will CMS Delay the Implementation of MACRA?
Jessica Miller
Rheumatology Practice Management August 2016 Vol 4 No 4 published on August 25, 2016 in Reimbursement
Referring Radical Prostatectomies to High-Volume Providers Could Save Millions
Chase Doyle
Urology Practice Management - August 2016, Vol 5, No 4 published on August 15, 2016 in Prostate Cancer
Implementation of ICD-10—Is That It?
Karna W. Morrow, CPC, RCC, CCS-P, PCS
Rheumatology Practice Management April 2016 Vol 4 No 2 published on May 18, 2016 in Reimbursement
From MACRA to MIPS: The New Incentives System for Providers
Chase Doyle
Urology Practice Management - April 2016, Vol 5, No 2 published on May 4, 2016 in Reimbursement
From MACRA to MIPS: The Impact of New Payment Systems on Providers
Chase Doyle
Rheumatology Practice Management February 2016 Vol 4 No 1 published on March 10, 2016 in Payment Models
CMS Reimbursement Policies Resulted in Overuse of Office-Based Cystoscopic Procedures
Rosemary Frei, MSc
Urology Practice Management - February 2016, Vol 5, No 1 published on February 19, 2016 in Reimbursement
Mastering the Crucial Conversation
Chase Doyle
Rheumatology Practice Management December 2015 Vol 3 No 6 published on January 18, 2016 in Leadership
Understanding Risks and Benefits: A Biosimilar Primer
Chase Doyle
Rheumatology Practice Management December 2015 Vol 3 No 6 published on January 18, 2016 in Biosimilars
ASCO Calls for “Transformative Approach” to Resolve Site-Neutrality Reimbursement
Charles Bankhead
Oncology Practice Management - December 2015, Vol 5, No 9 published on December 22, 2015 in Reimbursement
Last modified: May 20, 2016
  • American Health and Drug Benefits
  • Lynx CME
  • Value Based Care in Rheumatology
  • Oncology Practice Management
  • Urology Practice Management